UNSPSC 51241127: Verteporfin

This classification denotes a porphyrin and photosensitizing agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X9PA28K43. European Medicines Agency schedules Verteporfin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00044MIG. Verteporfin generally arises in the molecular formula C41H42N4O8. The term VERTEPORFIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 3, 2004, list 52.) Most nations schedule Verteporfin under HS 29339990 and SITC 51577.

SMILES:. As of Q4 2014, VERTEPORFIN remains the US FDA Preferred Term for this commodity.. Verteporfin bears US NLM identifiers UMLS ID C0387288 and NCI Concept Code C1014.

UNSPSC 51241127 Verteporfin is a Commodity code for the photosensitizing agent verteporfin, a drug used in photodynamic therapy for age-related macular degeneration and other retinal conditions. State and local governments procure verteporfin primarily through health departments, public hospitals, outpatient surgery centers, and Medicaid agencies that operate or reimburse vision care and ophthalmology services. Procurement typically takes the form of standing pharmaceutical supply contracts or one-time purchases through group purchasing agreements and cooperative purchasing vehicles that leverage state-negotiated drug pricing.

The source provided contains no recent state or local contract opportunities tagged to this code. Without access to recent solicitation data, it is not possible to characterize the geographic distribution of buying activity, the mix of issuing bodies currently soliciting verteporfin, or representative recent RFP, RFQ, IFB, or ITB notices. Firms pursuing verteporfin supply contracts should monitor pharmaceutical procurement channels through state health departments, Medicaid purchasing offices, and hospital group purchasing organizations, as well as cooperative purchasing catalogs that aggregate state and local drug procurement.